Knight Therapeutics (KHTRF) has entered into a revolving credit facility with National Bank of Canada. Knight has withdrawn C$60 million from the Credit Facility to fund a portion of the Paladin acquisition. The Credit Facility provides Knight with an initial borrowing limit of up to $50 million, which is mainly intended to support the Company’s growth strategy and may also be used for working capital and other corporate purposes. The revolving credit facility is secured, and has an initial term of 3 years, which can be extended annually by an additional one-year terms. In addition, NBC has launched a syndication process, and it is expected that the size of the credit facility will be increased to $100 million plus an accordion of $50M within the next 6 months. The credit facility can be drawn in USD or CAD at the SOFR or CORRA rate plus an applicable margin between 1.25% to 2.75% depending on Knight’s debt leverage. Knight will pay stand-by fees for the undisbursed portion of the credit facility. In addition, the Credit Facility includes certain customary financial and non-financial covenants that the Company must maintain over the period of the agreement.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal
- Knight Therapeutics’ Earnings Call: Growth Amid Challenges
- Knight Therapeutics: Strong Buy Rating Amid Promising Financial Outlook and Strategic Resilience
- Knight Therapeutics Sees Revenue Growth Amid Strategic Moves
- Knight Therapeutics sees FY25 revenue C$390M-C$405M